Kenji Hayashibara

Publications (2)6.69 Total impact

• Article: Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004.

  Shun-Ichi Isa, Tomoya Kawaguchi, Satoshi Teramukai, Koichi Minato, Yoshinobu Ohsaki, Kazuhiko Shibata, Toshirou Yonei, Kenji Hayashibara, Masanori Fukushima, Masaaki Kawahara, Kiyoyuki Furuse, Philip C Mack
  [show abstract] [hide abstract]
  ABSTRACT: The Japan-Multinational Trial Organization (JMTO) lung cancer (LC) 0003 was a prospective randomized phase III trial investigating advanced non-small cell lung cancer comparing paclitaxel (P) plus carboplatin (C) versus vinorelbine (V), gemcitabine (G) followed by docetaxel (D). This trial was conducted with Southwest Oncology Group (SWOG) 0003 using a common arm of PC. An analysis of SWOG 0003 samples showed that low osteopontin (OPN) plasma levels were highly prognostic for a better outcome. We performed an independent investigation to validate these results using samples from Japanese patients enrolled in the JMTO LC 0004, a correlative study associated with JMTO LC 0003. A total of 20 ml of blood was collected before treatment from patients enrolled in JMTO LC 0003. Serum concentrations of OPN and basic fibroblast growth factor (bFGF) were measured by enzyme-linked immunosorbent assay. Effects of OPN and bFGF levels on tumor response, progression-free survival (PFS), and overall survival (OS) were examined. Seventy-one samples were obtained, including 32 specimens from the PC arm and 39 from the VGD arm. There were no significant relationships between either OPN or bFGF levels with patient characteristics. In an analysis of clinical outcome, low OPN levels correlated with better OS and progression-free survival (hazard ratio [HR] = 0.57; 95% confidence interval [CI], 0.33-0.97; p = 0.037, HR = 0.42; 95% CI, 0.25-0.70; p = 0.001, respectively) and high bFGF levels correlated with better OS (HR = 0.53; 95% CI, 0.31-0.90; p = 0.018). Consistent with the findings from SWOG 0003, low OPN serum levels were significantly associated with a favorable prognosis in the JMTO LC 0004. Additionally, high bFGF levels were associated with improved survival.
  Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 08/2009; 4(9):1104-10. · 4.55 Impact Factor
• Article: A population-based study of gefitinib in patients with non-small cell lung cancer.

  Kenji Hayashibara, Hiroaki Satoh, Yoko Shinohara, Masaharu Inagaki, Takayuki Kaburagi, Toshio Hashimoto, Koichi Kurishima, Hiroichi Ishikawa, Hideo Ichimura, Takeshi Nawa, Yasunori Funayama, Takeshi Matsumura, Katsunori Kagohashi, Takeshi Endo, Kinya Furukawa, Koji Kishi, Masaaki Sumi, Koichi Kamiyama, Shigemi Ishikawa
  [show abstract] [hide abstract]
  ABSTRACT: Survival data for non-small cell lung cancer is typically reported from clinical trials that include patients fit enough to meet treatment criteria. The denominator of all patients from which the gefitinib-treated population is derived has rarely been reported and the impact of gefitinib on population-based outcomes is difficult to measure. We have retrospectively reviewed data of 626 patients who received gefitinib in Ibaraki Prefecture (with a population of 3 million) in Japan from July 2002 until September 2007. Overall response rate was found to 30.8%, and the median survival time was 8.0 months (95% confidence interval: 7.0-9.0 months). Female gender, good PS, and adenocarcinoma were significantly associated with prolonged survival. Adverse events were generally mild and were mostly skin reactions and diarrhea. Our population-based study has generated similar results to those previously reported in published clinical trials, which had restrictive criteria for eligible patients.
  Medical Oncology 11/2008; 26(2):222-7. · 2.14 Impact Factor